Cargando…
Trametinib potentiates TRAIL‐induced apoptosis via FBW7‐dependent Mcl‐1 degradation in colorectal cancer cells
Trametinib is a MEK1/2 inhibitor and exerts anticancer activity against a variety of cancers. However, the effect of Trametinib on colorectal cancer (CRC) is not well understood. In the current study, our results demonstrate the ability of sub‐toxic doses of Trametinib to enhance TRAIL‐mediated apop...
Autores principales: | Lin, Lin, Ding, Dapeng, Xiao, Xiaoguang, Li, Bing, Cao, Penglong, Li, Shijun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299726/ https://www.ncbi.nlm.nih.gov/pubmed/32352219 http://dx.doi.org/10.1111/jcmm.15336 |
Ejemplares similares
-
FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation
por: Tong, Jingshan, et al.
Publicado: (2016) -
SCF(Fbw7) Regulates Cellular Apoptosis By Targeting Mcl-1 for Ubiquitination and Destruction
por: Inuzuka, Hiroyuki, et al.
Publicado: (2011) -
Metformin enhances TRAIL-induced apoptosis by Mcl-1 degradation via Mule in colorectal cancer cells
por: Park, Seong Hye, et al.
Publicado: (2016) -
Mcl‐1 inhibition overcomes BET inhibitor resistance induced by low FBW7 expression in breast cancer
por: Wang, Xu, et al.
Publicado: (2022) -
Fbw7 dimerization determines the specificity and robustness of substrate degradation
por: Welcker, Markus, et al.
Publicado: (2013)